Physician profile
Danielle Delligatti
NPI 1336512771
$2,896.23
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $663 · 2022: $929 · 2023: $1,127 · 2024: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $497.85 | 2023-2024 | Watchman Flx, Watchman Access System |
| Impulse Dynamics (USA) INC. | $358.90 | 2022-2023 | Optimizer |
| Medtronic, INC. | $298.15 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $212.42 | 2021-2023 | Verquvo, Steglatro, Steglujan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187.41 | 2021-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $175.16 | 2021-2023 | Farxiga, Brilinta |
| Abbott Laboratories | $125.61 | 2022-2023 | Cardiomems, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.26 | 2021-2023 | Jardiance |
| Amgen INC. | $116.17 | 2021-2023 | Repatha |
| Novo Nordisk INC | $114.08 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $112.71 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $92.44 | 2021-2022 | |
| Cvrx, INC. | $73.90 | 2023 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $67.53 | 2022-2023 | Xarelto |
| Avanir Pharmaceuticals, INC. | $44.21 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $41.07 | 2022-2023 | Uptravi, Opsumit |
| Abbvie INC. | $41.02 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $39.58 | 2021 | |
| Tactile Systems Technology INC | $38.87 | 2021-2022 | |
| Biosense Webster, INC. | $34.11 | 2023 | Carto 3 |
| Lilly USA, LLC | $27.57 | 2021-2022 | |
| Eisai INC. | $21.88 | 2021 | |
| Tandem Diabetes Care, INC. | $15.98 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $14.85 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.27 | 2022 | |
| Gilead Sciences, INC. | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Delligatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.